Highlights
- Paradigm Biopharmaceuticals (ASX:PAR) continues advancing its Phase 3 osteoarthritis trial for Zilosul.
- The company completed enrolment of 538 participants across 65 clinical sites.
- An independent safety and futility review is expected during September 2026.
- Top-line efficacy results are targeted for the first quarter of 2027.
Paradigm Biopharmaceuticals (ASX:PAR) remains focused on advancing its lead clinical programme, with investor attention centred on upcoming milestones from its Phase 3 osteoarthritis study. The company’s shares were trading at AUD 0.18, unchanged at the time of writing on 21 August 2026.
The company continues progressing its PARA_OA_012 Phase 3…
